The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6 DHA), eicosapentaenoic acid (20:5 EPA) and docosapentaenoic acid (22:5 DPA), or esters thereof in the manufacture of a composition for use in a method for treating, stabilizing or slowing down brain glucose metabolism deficit in a subject in need thereof.
